tetano
Editor, Senior Moderator
JMIR Public Health Surveill
. 2022 Mar 28;8(3):e25803.
doi: 10.2196/25803.
Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
Simon de Lusignan[SUP] 1 [/SUP], Ruby S M Tsang[SUP] 1 [/SUP], Oluwafunmi Akinyemi[SUP] 1 [/SUP], Jamie Lopez Bernal[SUP] 2 [/SUP], Gayatri Amirthalingam[SUP] 2 [/SUP], Julian Sherlock[SUP] 1 [/SUP], Gillian Smith[SUP] 2 [/SUP], Maria Zambon[SUP] 2 [/SUP], Gary Howsam[SUP] 3 [/SUP], Mark Joy[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Vaccination is the most effective form of prevention of seasonal influenza; the United Kingdom has a national influenza vaccination program to cover targeted population groups. Influenza vaccines are known to be associated with some common minor adverse events of interest (AEIs), but it is not known if the adjuvanted trivalent influenza vaccine (aTIV), first offered in the 2018/2019 season, would be associated with more AEIs than other types of vaccines.
Objective: We aim to compare the incidence of AEIs associated with different types of seasonal influenza vaccines offered in the 2018/2019 season.
Methods: We carried out a retrospective cohort study using computerized medical record data from the Royal College of General Practitioners Research and Surveillance Centre sentinel network database. We extracted data on vaccine exposure and consultations for European Medicines Agency-specified AEIs for the 2018/2019 influenza season. We used a self-controlled case series design; computed relative incidence (RI) of AEIs following vaccination; and compared the incidence of AEIs associated with aTIV, the quadrivalent influenza vaccine, and the live attenuated influenza vaccine. We also compared the incidence of AEIs for vaccinations that took place in a practice with those that took place elsewhere.
Results: A total of 1,024,160 individuals received a seasonal influenza vaccine, of which 165,723 individuals reported a total of 283,355 compatible symptoms in the 2018/2019 season. Most AEIs occurred within 7 days following vaccination, with a seasonal effect observed. Using aTIV as the reference group, the quadrivalent influenza vaccine was associated with a higher incidence of AEIs (RI 1.46, 95% CI 1.41-1.52), whereas the live attenuated influenza vaccine was associated with a lower incidence of AEIs (RI 0.79, 95% CI 0.73-0.83). No effect of vaccination setting on the incidence of AEIs was observed.
Conclusions: Routine sentinel network data offer an opportunity to make comparisons between safety profiles of different vaccines. Evidence that supports the safety of newer types of vaccines may be reassuring for patients and could help improve uptake in the future.
Keywords: adverse events of interest; computerized medical record systems; influenza; influenza vaccines; sentinel surveillance.
. 2022 Mar 28;8(3):e25803.
doi: 10.2196/25803.
Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study
Simon de Lusignan[SUP] 1 [/SUP], Ruby S M Tsang[SUP] 1 [/SUP], Oluwafunmi Akinyemi[SUP] 1 [/SUP], Jamie Lopez Bernal[SUP] 2 [/SUP], Gayatri Amirthalingam[SUP] 2 [/SUP], Julian Sherlock[SUP] 1 [/SUP], Gillian Smith[SUP] 2 [/SUP], Maria Zambon[SUP] 2 [/SUP], Gary Howsam[SUP] 3 [/SUP], Mark Joy[SUP] 1 [/SUP]
Affiliations
- PMID: 35343907
- DOI: 10.2196/25803
Abstract
Background: Vaccination is the most effective form of prevention of seasonal influenza; the United Kingdom has a national influenza vaccination program to cover targeted population groups. Influenza vaccines are known to be associated with some common minor adverse events of interest (AEIs), but it is not known if the adjuvanted trivalent influenza vaccine (aTIV), first offered in the 2018/2019 season, would be associated with more AEIs than other types of vaccines.
Objective: We aim to compare the incidence of AEIs associated with different types of seasonal influenza vaccines offered in the 2018/2019 season.
Methods: We carried out a retrospective cohort study using computerized medical record data from the Royal College of General Practitioners Research and Surveillance Centre sentinel network database. We extracted data on vaccine exposure and consultations for European Medicines Agency-specified AEIs for the 2018/2019 influenza season. We used a self-controlled case series design; computed relative incidence (RI) of AEIs following vaccination; and compared the incidence of AEIs associated with aTIV, the quadrivalent influenza vaccine, and the live attenuated influenza vaccine. We also compared the incidence of AEIs for vaccinations that took place in a practice with those that took place elsewhere.
Results: A total of 1,024,160 individuals received a seasonal influenza vaccine, of which 165,723 individuals reported a total of 283,355 compatible symptoms in the 2018/2019 season. Most AEIs occurred within 7 days following vaccination, with a seasonal effect observed. Using aTIV as the reference group, the quadrivalent influenza vaccine was associated with a higher incidence of AEIs (RI 1.46, 95% CI 1.41-1.52), whereas the live attenuated influenza vaccine was associated with a lower incidence of AEIs (RI 0.79, 95% CI 0.73-0.83). No effect of vaccination setting on the incidence of AEIs was observed.
Conclusions: Routine sentinel network data offer an opportunity to make comparisons between safety profiles of different vaccines. Evidence that supports the safety of newer types of vaccines may be reassuring for patients and could help improve uptake in the future.
Keywords: adverse events of interest; computerized medical record systems; influenza; influenza vaccines; sentinel surveillance.